A preliminary evaluation of the effect of N‐acetyl‐aspartyl‐glutamate on pollen nasal challenge as measured by rhinomanometry and symptomatology

Abstract

The preventive effect of a nasally administered single dose of the dipeptide N-acetyl-aspartyl-glutamate (NAAGA) on pollen-induced early nasal reaction as measured by rhinomanometry and symptomatology was investigated in a double-blind cross-over placebo controlled study in 18 patients with nasal sensitization to grass pollen. Mean nasal airways resistance at 20, 40, and 60 min post challenge was, respectively, 33%, 37% (P = 0.03) and 27% less after NAAGA than after placebo administration in the same patients. In contrast, no significant effect on sneeze count and rhinorrhoea was found.

Modulation of allergen-induced nasal symptoms and mediator release by treatment with N-acetyl-aspartyl-glutamate (ZY15106)

“…In addition, Ghaem (1987) observed that a single dose of ZY15106 reduced the allergen-induced nasal obstruction as measured by anterior nasal rhinomanometry. These clinical findings may be explained, at least in part, by our results showing that 1-week local treatment with ZY15106 attenuates antigen-induced histamine and iLTC4 release in the nasal airways of allergic rhinitics.…”

“…Moreover, ZY15106 was shown to inhibit mast cell degranulation induced by immunological and nonimmunological stimuli (Secchi et al 1987). In vivo, ZY15106 was proven to be able to reduce allergenevoked nasal symptoms (Ghaem et al 1987).…”

Effect of an inhaled mast cell stabiliser, N‐acetyl‐aspartyl‐glutamate (Zy15109) on allergen‐induced immediate bronchoconstriction.

“…An obvious example is the ability of sodium cromoglycate to inhibit the activation of human lung mast cells, but not skin mast cells (Clegg et al, 1985;Church, 1986). Thus, although NAAGA inhibits mast cell activation in the guinea-pig and partially inhibits the early nasal response to allergen challenge in human (Ghaem, 1987), it is not surprising to find that it is unable to protect the human lung mast cells against allergen challenge. Another possibility for its ineffectiveness could be due to an insufficient dose of aerosol administered, although a 3% solution of NAAGA was previously shown to be effective in stabilising guinea-pig mast cells.…”

“…In addition, NAAGA also inhibits activation of complement by both the classical and alternative pathways (unpublished data). This dipeptide, when administered as a nasal spray, has been shown to reduce allergen-induced nasal obstruction in patients with allergic rhinitis (Ghaem, 1987 None of them took any medication for at least 3 months prior to the study, or any time during the study. The study was approved by the Southampton University and Hospitals Ethics Sub-committee and written informed consent was obtained from each subject.…”

“…In addition, NAAGA also inhibits activation of complement by both the classical and alternative pathways (unpublished data). This dipeptide, when administered as a nasal spray, has been shown to reduce allergen-induced nasal obstruction in patients with allergic rhinitis (Ghaem, 1987). As mast cells play an important role in the pathogenesis of allergen-induced early asthmatic response (EAR) (Lai & Holgate, 1988), one may expect mast cell stabilising agents such as NAAGA to have an inhibitory effect on the EAR.…”